4.2 Article

Urinary 11-dehydro-thromboxane B2 levels are associated with vascular inflammation and prognosis in atherosclerotic cardiovascular disease

Journal

PROSTAGLANDINS & OTHER LIPID MEDIATORS
Volume 134, Issue -, Pages 24-31

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.prostaglandins.2017.11.003

Keywords

Thromboxane; Prostacyclin; Cyclooxygenase; Eicosanoids; Inflammation; Atherosclerotic cardiovascular disease; Prognosis; Humans

Funding

  1. American Heart Association [16GRNT29300003, 11PRE7240059]
  2. predoctoral training program in Integrative Vascular Biology
  3. NIH/NHLBI [T32 HL069768]
  4. UNC University Research Council
  5. NIH National Center for Advancing Translational Sciences [1UL1TR001111]
  6. NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001111, UL1TR002489] Funding Source: NIH RePORTER
  7. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL069768] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Cyclooxygenase-derived thromboxane (TxA2) and prostacyclin (PGI2) regulate atherogenesis in preclinical models. However, the relationship between TxA2 and PGI2 biosynthesis, vascular inflammation, and atherosclerotic cardiovascular disease (ASCVD) progression in humans remains unclear. The association between stable urine metabolites of thromboxane (TxA2-M) and prostacyclin (PGI2-M), circulating levels of cellular adhesion molecules (CAMs: E-selectin, P-selectin), chemokines and C-reactive protein, and the incidence of major adverse cardiovascular events (MACE) were evaluated in 120 patients with stable ASCVD on aspirin therapy. Urinary TxA2-M levels were significantly correlated with circulating P-selectin (r = 0.319, p < 0.001) and E-selectin (r = 0.245, p = 0.007) levels, and associated with higher risk of MACE (p = 0.043). In contrast, PGI2-M levels were not significantly associated with CAM levels or MACE. These results provide insight into the contribution of TxA2 biosynthesis to ASCVD progression in humans, and suggest that patients with elevated TxA2-M levels may be predisposed to advanced platelet and endothelial activation and higher risk of adverse cardiovascular outcomes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available